Prognostic Value of Helix Pomatia in Breast Cancer
Author Information
Author(s): B.A. Gusterson, C.W. Taylor, K.N. Price, R.D. Gelber, J. Save-S6derbergh, R. Anbazhagan, H. Jayatilake, C.-M. Rudenstam, R. Reed, L. Morassi, P. Grigolato, M. Zorzi, R. Bettelheim, A.M. Neville, G.C. Hitchcock, M. Jagush, A. Tiltman, H.G. Schniirch, H. Bender, R. Golouh, J. Lamovec, J. Jancar, F. Martinez-Tello, K.B. Shilkin, G. Locher, K. Biirki, M. Stanisic, Th. Hardmeier, P. Luscieti, E. Passega, J. Torhorst, R.P. Baumann, E. Jacot-des-Coombes, P. Anani, A. Ng, M. Castiglione, H.-J. Senn, A. Goldhirsch
Hypothesis
Does Helix pomatia lectin binding correlate with survival outcomes in breast cancer patients?
Conclusion
Helix pomatia lectin binding has no clinical predictive value for breast cancer outcomes.
Supporting Evidence
- There was a weak correlation between lymph node-positive and HPA positive (P = 0.04).
- Node-negative patients had a large advantage in disease-free survival and overall survival (P<0.0001).
- HPA-negative patients showed no advantage in survival outcomes (P = 0.23 for DFS and P = 0.32 for OS).
Takeaway
This study looked at a lot of breast cancer cases to see if a certain test could help predict how well patients would do, but it found that the test didn't really help.
Methodology
The study analyzed 684 breast cancer cases for Helix pomatia lectin binding and its correlation with clinical outcomes.
Limitations
The study did not find correlations with several prognostic factors and had a limited ability to predict outcomes based on HPA positivity.
Statistical Information
P-Value
0.04
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website